Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

9. november 2026 opdateret af: Haibo Shao

A Multicenter, Prospective, Single-arm Clinical Study Evaluating the Efficacy and Safety of Epalrestat Combined With Hepatic Arterial Chemotherapy Infusion (HAIC), Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable Hepatocellular Carcinoma and Diabetes

The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

32

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150085
        • Ikke rekrutterer endnu
        • Harbin Medical University Cancer Hospital
        • Kontakt:
    • Jilin
      • Yanji, Jilin, Kina, 133000
        • Rekruttering
        • Yanbian University Hospital
        • Kontakt:
    • Liaoning
      • Shenyang, Liaoning, Kina, 110000
        • Aktiv, ikke rekrutterende
        • The First Hospital of China Medical University
      • Shenyang, Liaoning, Kina, 110001
        • Ikke rekrutterer endnu
        • Liaoning Cancer Hospital
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Diabetes mellitus combined with unresectable advanced HCC (BCLC stage C);
  2. Patients who have the need for treatment, prevention and improvement of diabetic neuropathy;
  3. Liver function at Child-Pugh grade A or B (≤ 7 points), ECOG PS 0-1;
  4. Age 18-80 years old. Confirmed as unrectable HCC through pathological or imaging diagnosis;

Exclusion Criteria:

  1. Severe liver dysfunction: Child-Pugh C grade (≥ 8 points) or active hepatic encephalopathy Illness;
  2. Extensive extrahepatic metastases (e.g., lung, bone, or peritoneum metastases);
  3. Severe cardiovascular diseases: Uncontrolled heart failure, recent myocardial infarction;
  4. Renal failure: Creatinine clearance rate < 30 mL/min;
  5. Thrombocytopenia (less than 50×10⁹/L) or coagulation dysfunction (INR greater than 1.5);
  6. Active infection (such as uncontrolled hepatitis B virus replication with HBV-DNA > 2000 IU/mL);
  7. ECOG PS ≥ 2 or extremely poor overall condition;
  8. Diabetic patients with acute ketoacidosis or during the period of severe infection;
  9. Pregnant and lactating women;
  10. Known history of other malignancy.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Epalrestat plus HAIC, donafenib and tislelizumab

Epalrestat 50mg tid, donafenib 0.2g bid, tislelizumab 200mg per 21days, HAIC (FOLFOX or RALOX) per 21days

For the first 6 patients in the safety lead-in period, the starting dose of epalrestat was 50 mg, three times per day. If dose-limiting toxicity (DLT) occurred in the first 6 patients, the dose for the second round of 6 patients in the safety lead-in period would be adjusted to 50 mg, twice per day. If DLT occurred in the second round of 6 patients, the dose for the third round of 6 patients in the safety lead-in period would be adjusted to 50 mg, once per day.

donafenib 0.2g BID, tislelizumab 200mg/21days

Include FOLFOX and RALOX.

Andre navne:
  • hepatic artery infusion chemotherapy

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
12-month Event-free survival (EFS) Rate
Tidsramme: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.

The proportion of patients who have remained event-free from the start of treatment until the 12-month time point.(Predefined events include: progression of disease, death for any reason, terminate the treatment due to intolerable AEs.)

From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Event-free survival (EFS)
Tidsramme: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.

Defined as the time from treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs).

From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
Overall survival (OS)
Tidsramme: Up to approximately 2 years

The OS is defined as the time from the enrollment to death due to any cause.

Up to approximately 2 years
Progression free survival(PFS) (Overall)
Tidsramme: From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.

The PFS is defined as the time from the enrollment to the first documented progressive disease (according to mRECIST) or death due to any cause, whichever occurs first.

From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.
Progression free survival(PFS) of intra-hepatic lesions
Tidsramme: From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.

The PFS is defined as the time from the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, whichever occurs first.

From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.
Progression free survival(PFS) of extra-hepatic lesions
Tidsramme: From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.

The PFS is defined as the time from the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, whichever occurs first.

From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.
Objective response rate(ORR) per RESCIST 1.1
Tidsramme: Up to approximately 2 years

The ORR is defined as the proportion of patients with a documented complete response(CR) or partial response(PR) per RECIST 1.1.

Up to approximately 2 years
ORR per mRECIST
Tidsramme: Up to approximately 2 years

The ORR is defined as the proportion of patients with a documented CR or PR per mRECIST.

Up to approximately 2 years
PVTT response rate per mRECIST
Tidsramme: Up to approximately 2 years

The PVTT response rate is defined as the proportion of patients with a documented CR or PR of PVTT.

According to the Vp classification:

CR: PVTT disappears or the portal vein becomes completely unobstructed. PR: Decrease in VP classification. SD: Without PR and PD. PD: Increase in VP classification.

Up to approximately 2 years
Disease control rate(DCR) per RESCIST 1.1
Tidsramme: Up to approximately 2 years

The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per RECIST 1.1.

Up to approximately 2 years
DCR per mRECIST
Tidsramme: Up to approximately 2 years

The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per mRECIST.

Up to approximately 2 years
Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0
Tidsramme: Up to approximately 2 years

The percentage and degree of patients who experience at least one AE, whether or not considered related to the treatment, according to CTCAE version 5.0.

Up to approximately 2 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Haibo Shao, First Hospital of China Medical University
  • Ledende efterforsker: Tao Han, First Hospital of China Medical University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. januar 2026

Primær færdiggørelse (Anslået)

1. december 2029

Studieafslutning (Anslået)

1. december 2030

Datoer for studieregistrering

Først indsendt

22. april 2026

Først indsendt, der opfyldte QC-kriterier

22. april 2026

Først opslået (Faktiske)

30. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • kelunshen【2025】2025-861-2

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Consent and privacy: Participants usually only agreed to data use in the original study. Sharing IPD may violate that agreement. And we want to protect our academic credit and avoid misuse of the data.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .